Fulgent Genetics (FLGT) Expected to Announce Quarterly Earnings on Friday

Fulgent Genetics (NASDAQ:FLGT) will likely be posting its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $85.38 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 8:30 AM ET.

Fulgent Genetics Stock Up 2.0%

NASDAQ FLGT opened at $23.56 on Thursday. The stock has a market capitalization of $728.24 million, a P/E ratio of -16.95 and a beta of 0.86. Fulgent Genetics has a 52-week low of $14.57 and a 52-week high of $31.04. The firm has a 50-day moving average price of $25.98 and a 200 day moving average price of $24.87.

Insider Activity

In other news, COO Jian Xie sold 1,198 shares of the firm’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $29.57, for a total transaction of $35,424.86. Following the completion of the transaction, the chief operating officer directly owned 337,889 shares of the company’s stock, valued at $9,991,377.73. This trade represents a 0.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Hanlin Gao sold 1,075 shares of Fulgent Genetics stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $28.33, for a total value of $30,454.75. Following the transaction, the insider owned 952,890 shares of the company’s stock, valued at $26,995,373.70. This represents a 0.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 4,356 shares of company stock valued at $126,060 over the last 90 days. 31.76% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Fulgent Genetics

A number of large investors have recently bought and sold shares of FLGT. ExodusPoint Capital Management LP acquired a new position in shares of Fulgent Genetics in the fourth quarter valued at approximately $367,000. Magnetar Financial LLC acquired a new stake in Fulgent Genetics during the fourth quarter worth approximately $321,000. Headlands Technologies LLC grew its stake in Fulgent Genetics by 26.9% in the 4th quarter. Headlands Technologies LLC now owns 12,046 shares of the company’s stock worth $316,000 after acquiring an additional 2,553 shares during the period. Franklin Resources Inc. raised its holdings in Fulgent Genetics by 27.1% in the 4th quarter. Franklin Resources Inc. now owns 13,868 shares of the company’s stock valued at $364,000 after acquiring an additional 2,955 shares during the last quarter. Finally, Mackenzie Financial Corp raised its holdings in Fulgent Genetics by 11.2% in the 3rd quarter. Mackenzie Financial Corp now owns 12,155 shares of the company’s stock valued at $275,000 after acquiring an additional 1,220 shares during the last quarter. Institutional investors and hedge funds own 48.06% of the company’s stock.

Analyst Ratings Changes

FLGT has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a research note on Thursday, January 22nd. Zacks Research downgraded Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Wall Street Zen lowered shares of Fulgent Genetics from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Piper Sandler upped their price target on shares of Fulgent Genetics from $21.00 to $30.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $36.00 price target on shares of Fulgent Genetics in a report on Friday, November 14th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $32.00.

About Fulgent Genetics

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.